BRAF and thyroid tumor: In total, 23/26 tumors express oncoproteins that activate mitogen-activated protein kinase (MAPK) signals, which confirms the critical role of activating this pathway in thyroid tumor formation, including the fusion of ETV6-NTRK3 and AGK-BRAF kinases that encode activated kinases that can be targeted pharmacologically.